Board of directors

Chairman, board member since 2024; chair of the Compensation & benefits committee, and the Transaction committee; member of the Audit committee, and the Scientific committee.

Born 1963; American national.

Education: Bachelor of Arts (Management) from the University of Cincinnati, USA.

Other assignments: member of the Board of Directors of Cullinan Therapeutics, uniQure (chair), and the University of Southern California School of Pharmacy and Pharmaceutical Sciences.

Prior experience: CEO and Board Director of Mirati Therapeutics Inc, FerGene Inc, and Ipsen SA. Senior executive positions at Baxalta Inc, Endocyte Inc, Novartis Pharmaceuticals, and Johnson & Johnson.

Independent of Sobi and its executive management: Yes

Independent in relation to major shareholders of Sobi: Yes

Shares in Sobi: 0.

Board member since 2023; member of the Compensation & benefits committee.

Born 1970; French and German national.

Education: Master of Business Administration from the International Institute for Management Business School, Switzerland and Bachelor of Arts from ISG Business School, France.

Other assignments: CEO of Leo Pharma A/S.

Prior experience: CEO of Orphazyme A/S. Senior Vice President, General Manager, US Oncology Business and member of the Operating Team at Amgen Inc. Senior Vice President of Europe, Middle East, Africa and Canada at Alexion. Other key roles within the international pharmaceutical industry.

Independent of Sobi and its executive management: Yes

Independent in relation to major shareholders of Sobi: Yes

Shares in Sobi: 0.

Board member since 2025; member of the Scientific committee, and the Transaction committee.

Born 1960; German national.

Education: MD, PhD in internal medicine from Goethe University Frankfurt, Germany.

Other assignments: Chair of the Board of Evotec SE and Celosia Therapeutics Pty Ltd. Board member of Fresenius SE & Co. KGaA. Member of the advisory boards of Spave Science Inc., Fondazione Telethon, Pierre Fabre S.A., and Helmholtz Health.

Prior experience: Executive Vice President, Chief Medical Officer and Head of Development at UCB S.A./Schwarz Pharma AG, Vice President, Head of Global Development at BASF Pharma, and various positions in clinical development at Aventis/Hoechst Marion Roussel/Hoechst AG (changed names due to mergers). 

Independent of Sobi and its executive management: Yes

Independent in relation to major shareholders of Sobi: Yes

Shares in Sobi: 0.
 

Board member since 2024; member of the Compensation & benefits committee.

Born 1970; Swedish national.

Education: Master of Science in Mechanical Engineering from Lund University, Sweden.

Other assignments: CEO of Mölnlycke Health Care AB.

Prior experience: President and CEO at CellaVision, Executive Vice President Sales & Marketing at ORIGO, President GBU Chronic at Gambro, Director Patient Handling Product Division at ArjoHuntleigh. 

Independent of Sobi and its executive management: Yes

Independent in relation to major shareholders of Sobi: No

Shares in Sobi: 10,000.
 

Board member since 2011; chair of the Audit committee.

Born 1970; Swedish national.

Education: Master of Science from Stockholm School of Economics, Sweden.

Other assignments: Board member of H&M, SEB, and Stockholm School of Economics.

Prior experience: CFO and Vice President at Investor AB. CFO at Hallvarsson & Halvarsson. Financial analyst at Goldman Sachs. Board member of Aleris and Mölnlycke Health Care.

Independent of Sobi and its executive management: Yes

Independent in relation to major shareholders of Sobi: No

Shares in Sobi: 22,856.

Board member since 2020; member of the Audit committee and the Transaction committee.

Born 1969; Swedish national.

Education: Bachelor of Arts (Hons) in business administration from the London Guildhall University, UK.

Other assignments: CEO of the ESTEVE Group. Board member of Dizlin Pharmaceuticals AB and Corporacíon Químico Farmacéutical Esteve S.A.

Prior experience: More than 20 years of experience from board and executive management roles, including several senior positions within Lundbeck A/S, such as Regional Vice President for Southern and Western Europe, President and Chairman of the US operations and Global Chief Commercial Officer on Group level.

Independent of Sobi and its executive management: Yes

Independent in relation to major shareholders of Sobi: Yes

Shares in Sobi: 7,142.

Board member since 2021; member of the Audit committee, the Compensation & benefits committee, and the Transaction committee.

Born 1985; Swedish national.

Education: Master of Science in economics from Stockholm School of Economics, Sweden.

Other assignments: Managing Director at Investor AB. Board member of Affibody Medical AB. Deputy Board member of Mölnlycke Health Care.

Prior experience: Chief Strategy Officer at Atlas Antibodies. Analyst at Swedbank LC&I.

Independent of Sobi and its executive management: Yes

Independent in relation to major shareholders of Sobi: No

Shares in Sobi: 571.

Board member since 2023; chair of the Scientific committee.

Born 1956; Swedish national.

Education: MD, PhD in clinical pharmacology, Gothenburg University, Sweden.

Other assignments: Board member of Verona Pharma plc.

Prior experience: Head of Research & Development and Medical Affairs and Chief Medical Officer at Sobi 2022-2023. Head of the COPD centre at the Sahlgrenska University Hospital 2015-2020. Board member of Sobi from May 2021 to December 2021, Board member of NeuroSearch and PExA. More than 20 years of experience from several executive positions within research and development in the international pharmaceutical industry, including Baxter Bioscience, Nycomed/Takeda, Biovitrum, Bayer Pharmaceuticals and AstraZeneca.

Independent of Sobi and its executive management: No

Independent in relation to major shareholders of Sobi: Yes

Shares in Sobi: 3,429.

Board member, employee representative since 2023.

Born 1983; Swedish national.

Education: Bachelor of Science in Mechanical Engineering Royal Institute of Technology (KTH), Stockholm, Sweden.

Sobi position: Business Controller Technical Operations.

Independent of the company and its executive management: No.

Independent in relation to major shareholders of the Company: Yes. 

Shares in Sobi: 138.

Deputy for the employee representatives since 2023.

Born 1962; Swedish nationality.

Education: PhD Pharmacology, Uppsala University, Sweden.

Sobi position: Global Safety Scientist, Global Pharmacovigilance and Patient Safety (GVP). 

Independent of the company and its executive management: No

Independent in relation to major shareholders of the Company: Yes

Shares in Sobi: 1,142.